• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Kobe 2602

Kobe 2602

Product ID K5606
Cas No. 454453-49-7
Purity ≥98%
Product Unit SizeCostQuantityStock
10 mg $59.00 In stock
50 mg $177.00 In stock
100 mg $321.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Kobe 2602 is an inhibitor of Ras that exhibits anticancer chemotherapeutic activities. In vitro, this compound inhibits cell growth and induces apoptosis and in vivo, it decreases tumor growth.

Product Info

Cas No.

454453-49-7

Purity

≥98%

Formula

C14H9F4N5O4S

Formula Wt.

419.31

Chemical Name

2-[2,6-Dinitro-4-(trifluoromethyl)phenyl]-N-(4-fluorophenyl)hydrazinecarbothioamide

IUPAC Name

2-[2,6-Dinitro-4-(trifluoromethyl)phenyl]-N-(4-fluorophenyl)hydrazinecarbothioamide

Synonym

2-[2,6-Dinitro-4-(trifluoromethyl)phenyl]-N-(4-fluorophenyl)hydrazinecarbothioamide

Solubility

DMSO: 15 mg/mL

Appearance

Light yellow solid

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

K5606 MSDS PDF

Info Sheet

K5606 Info Sheet PDF

References

Shima F, Yoshikawa Y, Ye M, et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc Natl Acad Sci U S A. 2013 May 14;110(20):8182-7. PMID: 23630290.

Shima F, Yoshikawa Y, Matsumoto S, et al. Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras·GTP-effector interaction. Enzymes. 2013;34 Pt. B:1-23. PMID: 25034098.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • L0251

    Laminin Peptide CDPGYIGSR

    Laminin-derived nonapeptide.

    ≥98%
  • C6019

    C-Peptide, human

    Endogenous peptide, connects A and B chains of ...

    ≥95%
  • C084099

    CCCP

    Efflux pump inhibitor

    ≥99%
  • V1668

    Vemurafenib

    B-Raf inhibitor.

    ≥98%
  • M568268

    Mogroside IV

    Triterpenoid

    ≥98%
  • V1854

    Venlafaxine Hydrochloride

    SERT, NET, MAO inhibitor.

    ≥98%
  • G1310

    GDC-0349

    mTOR inhibitor.

    ≥98%
  • I7558

    1-Isothiocyanato-9-(methylsulfenyl)-nonane

    ITC, erucin analog.

    ≥97%
  • T0118

    7-epi-Cephalomannine

    Cephalomannine derivative found in Taxus; poten...

    ≥95%
  • S0253

    Sanguinarine

    Benzophenanthridine alkaloid found in various p...

    ≥98%
  • R3012

    Recombinant TpN 17 protein

    Recombinant protein containing Treponema pallid...

    ≥95%
  • N3476

    Nitisinone

    Nitrobenzene; HPPD inhibitor.

    ≥99%
  • P4492

    PLX4720

    V600E B-Raf inhibitor.

    ≥98%
  • T5869

    Torcetrapib

    Cholesterol ester transfer protein inhibitor.

    ≥98%
  • C1876

    Cetirizine Dihydrochloride

    Histamine H1 antagonist.

    ≥99%
  • I525138

    Indoximod

    Indoleamine 2,3-dioxygenase inhibitor.

    ≥98%
  • M9644

    Myelin Basic Protein (87-99), guinea pig/human

    Immunodominant peptide epitope occurring in mul...

    ≥95%
  • T6903

    Tranylcypromine Hydrochloride

    MAO and histone demethylase LSD1 inhibitor.

    ≥98%
  • M7200

    MS436

    BRD4 inhibitor.

    ≥99%
  • L5769

    Lorglumide Sodium

    CCK antagonist.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only